{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:52:22Z","timestamp":1793267542687,"version":"4.5.0"},"reference-count":66,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of \u03b2-lactams\/\u03b2-lactamase inhibitors against multidrug-resistant (MDR) Gram-negative pathogens, which remain the major concern in clinical practice. The incorporation of ceftolozane\/tazobactam, ceftazidime\/avibactam, meropenem\/vaborbactam, and imipenem\/cilastatin\/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime\/enmetazobactam, avibactam\/aztreonam, and sulbactam\/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-\u03b2-lactamase producing Gram-negative bacteria. Currently, many combinations are being studied for their in vitro activity against both serine- and metallo-\u03b2-lactamases. However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime\/zidebactam, cefepime\/taniborbactam, and imipenem\/cilastatin\/funobactam, which are currently under investigation in phase 3 trials.<\/jats:p>","DOI":"10.3390\/pathogens14020168","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T04:44:03Z","timestamp":1739162643000},"page":"168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["\u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development"],"prefix":"10.3390","volume":"14","author":[{"given":"Angeliki","family":"Katsarou","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece"},{"name":"Department of Medicine, Hygeia Hospital, 4 Erythrou Stavrou Street, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Stathopoulos","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva D.","family":"Tzvetanova","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 6 Diogenous Street, 2404 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina-Maria","family":"Asimotou","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece"},{"name":"School of Medicine, European University Cyprus, 6 Diogenous Street, 2404 Nicosia, Cyprus"},{"name":"Department of Medicine, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, October 07). Antimicrobial Resistance. Published Online 21 November 2023. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"ref_3","first-page":"Doc05","article-title":"Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?","volume":"12","author":"Exner","year":"2017","journal-title":"GMS Hyg. Infect. Control"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Poudel, A.N., Zhu, S., Cooper, N., Little, P., Tarrant, C., Hickman, M., and Yao, G. (2023). The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285170"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/cid\/ciaa1581","article-title":"National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States","volume":"72","author":"Nelson","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_6","unstructured":"World Bank Group (2025, January 06). Drug-Resistant Infections. A Threat to Our Economic Future. Published Online March 2017. Available online: https:\/\/documents1.worldbank.org\/curated\/en\/323311493396993758\/pdf\/final-report.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","article-title":"on behalf of the French Intensive Care Society. Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","volume":"13","author":"Barbier","year":"2023","journal-title":"Ann. Intensive Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1503\/cmaj.109-4917","article-title":"US tries to stem antimicrobial resistance","volume":"186","author":"Webster","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/Enmetazobactam: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.clinthera.2024.06.007","article-title":"Ceftobiprole Medocaril Sodium","volume":"46","author":"Beninger","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_12","unstructured":"World Health Organization (2024, October 09). 2024 WHO Bacterial Priority Pathogens List. Published Online 2024. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Krco, S., Davis, S.J., Joshi, P., Wilson, L.A., Monteiro Pedroso, M., Douw, A., Schofield, C.J., Hugenholtz, P., Schenk, G., and Morris, M.T. (2023). Structure, function, and evolution of metallo-\u03b2-lactamases from the B3 subgroup\u2014Emerging targets to combat antibiotic resistance. Front. Chem., 11.","DOI":"10.3389\/fchem.2023.1196073"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Glen, K.A., and Lamont, I.L. (2021). \u03b2-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens, 10.","DOI":"10.3390\/pathogens10121638"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"\u010cerniauskien\u0117, K., Dambrauskien\u0117, A., and Vitkauskien\u0117, A. (2023). Associations between \u03b2-Lactamase Types of Acinetobacter baumannii and Antimicrobial Resistance. Medicina, 59.","DOI":"10.20944\/preprints202306.0826.v2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01484-18","DOI":"10.1128\/AAC.01484-18","article-title":"Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment","volume":"63","author":"Preston","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s15010-019-01291-9","article-title":"AmpC \u03b2-lactamase-producing Enterobacterales: What a clinician should know","volume":"47","author":"Meini","year":"2019","journal-title":"Infection"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e02529-16","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent \u201c\u03b2-Lactam Enhancer\u201d Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-\u03b2-Lactamase-Producing High-Risk Clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/jac\/dkx050","article-title":"WCK 5222 (cefepime\/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant \u03b2-lactamases","volume":"72","author":"Sader","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01726-20","DOI":"10.1128\/AAC.01726-20","article-title":"In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018","volume":"65","author":"Yang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e02146-18","DOI":"10.1128\/AAC.02146-18","article-title":"The Novel \u03b2-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model","volume":"63","author":"Bhagwat","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00948-18","DOI":"10.1128\/AAC.00948-18","article-title":"Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model","volume":"62","author":"Avery","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01931-18","DOI":"10.1128\/AAC.01931-18","article-title":"In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model","volume":"63","author":"Avery","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00500-23","DOI":"10.1128\/aac.00500-23","article-title":"Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia","volume":"67","author":"Tirlangi","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dubey, D., Roy, M., Shah, T.H., Bano, N., Kulshrestha, V., Mitra, S., Sangwan, P., Dubey, M., Imran, A., and Jain, B. (2023). Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: A case report. Ann. Clin. Microbiol. Antimicrob., 22.","DOI":"10.1186\/s12941-023-00606-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00682-18","DOI":"10.1128\/AAC.00682-18","article-title":"Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40265-024-02082-9","article-title":"Cefepime\u2013Taniborbactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination","volume":"84","author":"Zhanel","year":"2024","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01281-22","DOI":"10.1128\/aac.01281-22","article-title":"In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkab405","article-title":"Clinical exposure\u2013response relationship of cefepime\/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model","volume":"77","author":"Lasko","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkac446","article-title":"In vivo pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model","volume":"78","author":"Abdelraouf","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","unstructured":"Chris Dall (2024, November 10). FDA Rejects New Drug Application for Cefepime-Taniborbactam. Published Online 27 February 2024. Available online: https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship\/fda-rejects-new-drug-application-cefepime-taniborbactam."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime\u2013Taniborbactam in Complicated Urinary Tract Infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, S., Liao, X., Ding, T., and Ahn, J. (2024). Role of \u03b2-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. Antibiotics, 13.","DOI":"10.3390\/antibiotics13030260"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgar.2022.07.006","article-title":"In vitro and in vivo activities of a novel \u03b2-lactamase inhibitor combination imipenem\/XNW4107 against recent clinical Gram-negative bacilli from China","volume":"31","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_38","unstructured":"(2024, November 17). Evaluation of the Efficacy and Safety of Intravenous Imipenem\/Cilastatin\/XNW4107 in Comparison with Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05204368."},{"key":"ref_39","unstructured":"(2024, November 17). Imipenem\/Cilastatin-XNW4107 versus Imipenem\/Cilastatin\/Relebactam for Treatment of Participants with Bacterial Pneumonia (XNW4107-302, REITAB-2) (REITAB-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05204563."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00432-19","DOI":"10.1128\/AAC.00432-19","article-title":"Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105838","DOI":"10.1016\/j.ijantimicag.2019.10.019","article-title":"Meropenem\u2013nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model","volume":"55","author":"Asempa","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e02382-18","DOI":"10.1128\/AAC.02382-18","article-title":"Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine \u03b2-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model","volume":"63","author":"Asempa","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02596-17","DOI":"10.1128\/AAC.02596-17","article-title":"In Vivo Efficacy of Meropenem with a Novel Non-\u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model","volume":"62","author":"Monogue","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","unstructured":"Clinicaltrials.gov (2024, November 10). A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants with a Complicated Urinary Tract Infection. Published Online 15 May 2018, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03174795#study-overview."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e02229-19","DOI":"10.1128\/AAC.02229-19","article-title":"Safety and Pharmacokinetic Characterization of Nacubactam, a Novel \u03b2-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers","volume":"64","author":"Mallalieu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00440-23","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e00579-23","DOI":"10.1128\/aac.00579-23","article-title":"New boronate drugs and evolving NDM-mediated beta-lactam resistance","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ofac492.294","DOI":"10.1093\/ofid\/ofac492.294","article-title":"216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects","volume":"9","author":"Griffith","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_50","unstructured":"(2024, November 17). A DDI Study to Investigate PK and Safety of Cefiderocol in Combination with Xeruborbactam in Healthy Adult Participants, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06547554?intr=xeruborbactam&rank=1#study-plan."},{"key":"ref_51","unstructured":"(2024, November 17). P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo with Ceftibuten in Healthy Participants, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06079775?intr=xeruborbactam&rank=3."},{"key":"ref_52","unstructured":"(2024, November 17). PK & Safety Study of Xeruborbactam Oral Prodrug Combined with Ceftibuten in Participants With Renal Impairment, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06157242?intr=xeruborbactam&rank=2."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01330-23","DOI":"10.1128\/aac.01330-23","article-title":"First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic\/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects","volume":"68","author":"Huang","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","unstructured":"Sakoulas, G. (2025, January 06). George Sakoulas Innovative Pairing of Beta-Lactamase Inhibitors to Combat Multidrug-Resistant Gram-Negative Pathogens. NEJM J. Watch. 2024, NA57235. Available online: https:\/\/www.jwatch.org\/na57235\/2024\/04\/22\/innovative-pairing-beta-lactamase-inhibitors-comba."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_56","unstructured":"EMA (2024, November 16). New Antibiotic to Fight Infections Caused by Multidrug-Resistant Bacteria. Published Online 22 March 2024. Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-antibiotic-fight-infections-caused-multidrug-resistant-bacteria."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Carmeli, Y., Cisneros, J.M., Paul, M., Daikos, G.L., Wang, M., Torre-Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., and Zhao, Y. (2024). Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect. Dis., S1473309924004997.","DOI":"10.1016\/S1473-3099(24)00499-7"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","article-title":"Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa","volume":"75","author":"Moya","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e02161-21","DOI":"10.1128\/aac.02161-21","article-title":"In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain","volume":"66","author":"Bou","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Carcione, D., Siracusa, C., Sulejmani, A., Leoni, V., and Intra, J. (2021). Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080995"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e00397-20","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-\u03b2-lactamase inhibitors: An unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e01935-19","DOI":"10.1128\/AAC.01935-19","article-title":"Biochemical Activity of Vaborbactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13445","article-title":"Aspergillomarasmine A overcomes metallo-\u03b2-lactamase antibiotic resistance","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_66","unstructured":"(2025, January 06). ECDC Antimicrobial resistance surveillance in Europe 2023\u20132021 Data. Published Online 14 April 2024. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Antimicrobial%20resistance%20surveillance%20in%20Europe%202023%20-%202021%20data.pdf."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/2\/168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:36Z","timestamp":1760027376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/2\/168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["pathogens14020168"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14020168","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]}}}